Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

72293 1527666247HCLSReviewCanadaMay2018.pdf
Energy Boardroom

Novartis sees start of $2B dermatology opportunity with new EU Xolair approval

07.03.2014 / Fierce Pharma

On Thursday, Novartis won European approval for its injectable Xolair to treat chronic hives–the first such product cleared there for patients who don't respond to antihistamines alone.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: